Castration-resistant prostate cancer: potential targets and therapies

References

• KimWRyanCJAndrogen receptor directed therapies in castration-resistant metastatic prostate cancerCurr Treat Options Oncol201213218920022539224
   PubMed Web of Science ®Google Scholar
• BluemnEGNelsonPSThe androgen/androgen receptor axis in prostate cancerCurr Opin Oncol201224325125722327838
   PubMed Web of Science ®Google Scholar
• GreenSMMostaghelEANelsonPSAndrogen action and metabolism in prostate cancerMol Cell Endocrinol2012Epub Mar20
   Google Scholar
• ShiotaMYokomizoANaitoSIncreased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic targetJ Mol Endocrinol2011471R25R4121504942
   PubMed Web of Science ®Google Scholar
• FeldmanBJFeldmanDThe development of androgen-independent prostate cancerNat Rev Cancer200111344511900250
   PubMed Web of Science ®Google Scholar
• NadimintyNGaoACMechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectivesWorld J Urol201230328729522009116
   PubMed Web of Science ®Google Scholar
• GoliasChIliadisIPeschosDCharalabopoulosKAmplification and co-regulators of androgen receptor gene in prostate cancerExp Oncol20093113819300409
   PubMedGoogle Scholar
• GregoryCWHeBJohnsonRTA mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapyCancer Res200161114315431911389051
   PubMed Web of Science ®Google Scholar
• AgoulnikIUWeigelNLAndrogen receptor action in hormone-dependent and recurrent prostate cancerJ Cell Biochem200699236237216619264
   PubMed Web of Science ®Google Scholar
• CaiCChenSNgPIntratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitorsCancer Res201171206503651321868758
   PubMed Web of Science ®Google Scholar
• LiYHwangTHOsethLAAR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionOncogene2012Epub Jan23
   Google Scholar
• DehmSMTindallDJAlternatively spliced androgen receptor variantsEndocr Relat Cancer2011185R183R19621778211
   PubMed Web of Science ®Google Scholar
• DehmSMSchmidtLJHeemersHVVessellaRLTindallDJSplicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistanceCancer Res200868135469547718593950
   PubMed Web of Science ®Google Scholar
• WatsonPAChenYFBalbasMDConstitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProc Natl Acad Sci U S A201010739167591676520823238
   PubMed Web of Science ®Google Scholar
• SunSSprengerCCVessellaRLCastration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantJ Clin Invest201012082715273020644256
   PubMed Web of Science ®Google Scholar
• ChiKNBjartellADearnaleyDCastration resistant prostate cancer: from new pathophysiology to new treatment targetsEur Urol200956459460519560857
   PubMed Web of Science ®Google Scholar
• SiddiqueHRMishraSKKarnesRJSaleemMLupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapyClin Cancer Res201117165379539121712449
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• SnoekRChengHMargiottiKIn vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumorsClin Cancer Res2009151394719118031
   PubMed Web of Science ®Google Scholar
• RyanCJTindallDJAndrogen receptor rediscovered: the new biology and targeting the androgen receptor therapeuticallyJ Clin Oncol201129273651365821859989
   PubMed Web of Science ®Google Scholar
• KoreckijTDTraugerRJMontgomeryRBHE3235 inhibits growth of castration-resistant prostate cancerNeoplasia200911111216122519881957
   PubMed Web of Science ®Google Scholar
• SharifiNNew agents and strategies for the hormonal treatment of castration-resistant prostate cancerExpert Opin Investig Drugs2010197837846
   PubMed Web of Science ®Google Scholar
• HamadaADanesiRPriceDKAssociation of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancerUrology200770221722017826473
   PubMed Web of Science ®Google Scholar
• KeisnerSVShahSRJeanGWUsserySMDowellJERetrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancerAnn Pharmacother201044101538154420841515
   PubMed Web of Science ®Google Scholar
• NgoLSYeoAWongASTayMHEfficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, SingaporeAnn Acad Med Singapore2007361081181417987231
   PubMed Web of Science ®Google Scholar
• NakabayashiMOhWKJacobusSActivity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancerBJU Int2010105101392139619863532
   PubMed Web of Science ®Google Scholar
• DanilaDCMorrisMJde BonoJSPhase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerJ Clin Oncol20102891496150120159814
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRFongLPhase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyJ Clin Oncol20102891481148820159824
   PubMed Web of Science ®Google Scholar
• YangLPAbiraterone acetate: in metastatic castration-resistant prostate cancerDrugs201171152067207721985170
   PubMed Web of Science ®Google Scholar
• BartholomeuszCGonzalez-AnguloAMTargeting the PI3K signaling pathway in cancer therapyExpert Opin Ther Targets201216112113022239433
   PubMed Web of Science ®Google Scholar
• MorganTMKoreckijTDCoreyETargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayCurr Cancer Drug Targets20099223724919275762
   PubMed Web of Science ®Google Scholar
• Carrión-SalipDPanosaCMenendezJAAndrogen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligandsInt J Oncol2012Epub Jun6
   Google Scholar
• KrohnADiedlerTBurkhardtLGenomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate CancerAm J Pathol2012Epub Jun13
   Google Scholar
• LiYSuJDingZhangXPTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcomeJ Pathol201122419010021381033
   PubMed Web of Science ®Google Scholar
• MulhollandDJTranLMLiYCell autonomous role of PTEN in regulating castration-resistant prostate cancer growthCancer Cell201119679280421620777
   PubMed Web of Science ®Google Scholar
• BedollaRPrihodaTJKreisbergJIDetermining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activationClin Cancer Res200713133860386717606718
   PubMed Web of Science ®Google Scholar
• GhoshPMMalikSBedollaRKreisbergJIAkt in prostate cancer: possible role in androgen-independenceCurr Drug Metab20034648749614683476
   PubMed Web of Science ®Google Scholar
• DattaSRDudekHTaoXAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machineryCell19979122312419346240
   PubMed Web of Science ®Google Scholar
• NicholsonKMAndersonNGThe protein kinase B/Akt signalling pathway in human malignancyCell Signal200214538139511882383
   PubMed Web of Science ®Google Scholar
• RomashkovaJAMakarovSSNF-kappaB is a target of AKT in anti-apoptotic PDGF signallingNature19994016748869010485711
   PubMed Web of Science ®Google Scholar
• KharazihaPRodriguezPLiQTargeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cellsCell Death Dis20123e26222278289
   PubMed Web of Science ®Google Scholar
• LeongKGKarsanARecent insights into the role of Notch signaling in tumorigenesisBlood200610762223223316291593
   PubMed Web of Science ®Google Scholar
• ShinIYakesFMRojoFPKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localizationNat Med20028101145115212244301
   PubMed Web of Science ®Google Scholar
• DiehlJAChengMRousselMFSherrCJGlycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localizationGenes Dev19981222349935119832503
   PubMed Web of Science ®Google Scholar
• KreisbergJIMalikSNPrihodaTJPhosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancerCancer Res200464155232523615289328
   PubMed Web of Science ®Google Scholar
• KaarbøMMikkelsenOLMalerødLPI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cellsCell Oncol2010321–2112720203370
   PubMed Web of Science ®Google Scholar
• PohTWPervaizSLY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathwayCancer Res200565146264627416024628
   PubMed Web of Science ®Google Scholar
• SeolJWLeeYJKangHSWortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 proteinExp Oncol200527212012415995629
   PubMed Web of Science ®Google Scholar
• PosadasEMGulleyJArlenPMA phase II study of perifosine in androgen independent prostate cancerCancer Biol Ther20054101133113716138006
   PubMed Web of Science ®Google Scholar
• CheeKGLongmateJQuinnDIThe AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trialClin Genitourin Cancer20075743343718272025
   PubMed Web of Science ®Google Scholar
• MajumderPKFebboPGBikoffRmTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysNat Med200410659460115156201
   PubMed Web of Science ®Google Scholar
• LerutERoskamsTGoossensEMolecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC)J Clin Oncol20052316S3071
   Google Scholar
• GeorgeDAArmstrongAJCreelPA phase II study of RAD001 in men with hormone-refractory metastatic prostate cancerProc Genitourin Cancers Symp2008 Abstract 181
   Google Scholar
• RossRWManolaJOhWKPhase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG- PET assessment of RAD001 activityJ Clin Oncol200826Suppl Abstract 5069
   Google Scholar
• HanGYuJYChenYDThe usefulness of phosphorylated-signal transduction and activators of transcription 3 in detecting prostate cancer from negative biopsiesEur J Surg Oncol201238436737322261084
   PubMed Web of Science ®Google Scholar
• MoraLBBuettnerRSeigneJConstitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cellsCancer Res200262226659666612438264
   PubMed Web of Science ®Google Scholar
• ChenTWangLHFarrarWLInterleukin 6 activates androgen receptor- mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cellsCancer Res20006082132213510786674
   PubMed Web of Science ®Google Scholar
• LouWNiZYDyerKTweardyDJGaoACInterleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathwayProstate200042323924210639195
   PubMed Web of Science ®Google Scholar
• LiuXHeZLiCHHuangGDingCLiuHCorrelation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancerPathol Oncol Res2012181172321681602
   PubMed Web of Science ®Google Scholar
• FearonKCMcMillanDCPrestonTWinstanleyFPCruickshankAMShenkinAElevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancerAnn Surg1991213126311898691
   PubMed Web of Science ®Google Scholar
• DrachenbergDEElgamalAARowbothamRPetersonMMurphyGPCirculating levels of interleukin-6 in patients with hormone refractory prostate cancerProstate199941212713310477909
   PubMed Web of Science ®Google Scholar
• HeMYoungCYNew approaches to target the androgen receptor and STAT3 for prostate cancer treatmentsMini Rev Med Chem20099339540019275732
   PubMed Web of Science ®Google Scholar
• MadouxFKoenigMSessionsHModulators of STAT Transcription Factors for the Targeted Therapy of Cancer (STAT3 Inhibitors). In: National Center for Biotechnology Information (US)Probe Reports from the NIH Molecular Libraries Program [book on the Internet]Bethesda, MDNational Center for Biotechnology Information8282009 [updated March 25, 2011]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56232/Accessed July 17, 2012
   Google Scholar
• SunMLiuCNadimintyNLouWInhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasionProstate2012721828921538419
   PubMed Web of Science ®Google Scholar
• ShanmugamMKRajendranPLiFUrsolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude miceJ Mol Med (Berl)201189771372721465181
   PubMed Web of Science ®Google Scholar
• KimCKimMCKimSMChrysanthemum indicum L. Extract Induces Apoptosis through Suppression of Constitutive STAT3-Activation in Human Prostate Cancer DU145 CellsPhytother Res2012Epub Mar22
   Google Scholar
• KwonGTJungJISongHRPiceatannol inhibits migration and invasion of prostate cancer cells: possible mediation by decreased interleukin-6 signalingJ Nutr Biochem201223322823821497499
   PubMed Web of Science ®Google Scholar
• RizzoPOsipoCForemanKGoldeTOsborneBMieleLRational targeting of Notch signaling in cancerOncogene200827385124513118758481
   PubMed Web of Science ®Google Scholar
• WangXDLeowCCZhaJNotch signaling is required for normal prostatic epithelial cell proliferation and differentiationDev Biol20062901668016360140
   PubMed Web of Science ®Google Scholar
• LeongKGGaoWQThe Notch pathway in prostate development and cancerDifferentiation200876669971618565101
   PubMed Web of Science ®Google Scholar
• BelandiaBPowellSMGarcía-PedreroJMWalkerMMBevanCLParkerMGHey1, a mediator of notch signaling, is an androgen receptor corepressorMol Cell Biol20052541425143615684393
   PubMed Web of Science ®Google Scholar
• ShouJRossSKoeppenHde SauvageFJGaoWQDynamics of notch expression during murine prostate development and tumorigenesisCancer Res200161197291729711585768
   PubMed Web of Science ®Google Scholar
• MartinDBGiffordDRWrightMEQuantitative proteomic analysis of proteins released by neoplastic prostate epitheliumCancer Res200464134735514729644
   PubMed Web of Science ®Google Scholar
• WhelanJTKelloggAShewchukBMHewan-LoweKBertrandFENotch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expressionJ Cell Biochem20091075992100119479935
   PubMed Web of Science ®Google Scholar
• SantagataSDemichelisFRivaAJAGGED1 expression is associated with prostate cancer metastasis and recurrenceCancer Res200464196854685715466172
   PubMed Web of Science ®Google Scholar
• MieleLMiaoHNickoloffBJNOTCH signaling as a novel cancer therapeutic targetCurr Cancer Drug Targets20066431332316848722
   PubMed Web of Science ®Google Scholar
• WangZLiYBanerjeeSDown-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathwaysJ Cell Biochem2010109472673620052673
   PubMed Web of Science ®Google Scholar
• Bin HafeezBAdhamiVMAsimMTargeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activatorClin Cancer Res200915245245919147749
   PubMed Web of Science ®Google Scholar
• KongDBanerjeeSAhmadAEpithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cellsPLoS One201058e1244520805998
   PubMed Web of Science ®Google Scholar
• SteinMNDiPaolaRSMayerTMA randomized phase II study of bicalutamide (BIC) followed by placebo or gamma secretase inhibitor RO4929097 (RO492) in men with rising PSAJ Clin Oncol201230Suppl 5 Abstract 219
   Web of Science ®Google Scholar
• KimSHSehrawatASakaoKHahmERSinghSVNotch activation by phenethyl isothiocyanate attenuates its inhibitory effect on prostate cancer cell migrationPLoS One2011610e2661522039516
   PubMed Web of Science ®Google Scholar
• Cancer Institute of New JerseyBicalutamide and RO4929097 in treating patients with previously treated prostate cancerClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated June 21, 2011]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01200810 NLM identifier: NCT01200810Accessed July 17, 2012
   Google Scholar
• ViewegJImmunotherapy for advanced prostate cancerRev Urol20079Suppl 1S29S3817387370
   PubMedGoogle Scholar
• AdamoVNotoLFranchinaTEmerging targeted therapies for castration-resistant prostate cancerFront Endocrinol (Lausanne)201237322666217
   PubMedGoogle Scholar
• SlovinSRToward maximizing immunotherapy in metastatic castration-resistant prostate cancer – rationale for combinatorial approaches using chemotherapyFront Oncol201224322662316
   PubMedGoogle Scholar
• MoffattSPapasakelariouCWiehleSCristianoRSuccessful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugateGene Ther200613976177216453011
   PubMed Web of Science ®Google Scholar
• ZhangKQYangFYeJA Novel DNA/Peptide Combined Vaccine Induces PSCA-specific Cytotoxic T-lymphocyte Responses and Suppresses Tumor Growth in Experimental Prostate CancerUrology20127961410.e71410.e1322513035
   PubMed Web of Science ®Google Scholar
• van den EertweghAJVersluisJvan den BergHPCombined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialLancet Oncol201213550951722326922
   PubMed Web of Science ®Google Scholar
• ThakurALittrupPPaulENAdamBHeilbrunLKLumLGInduction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot studyJ Immunother201134545746721577139
   PubMed Web of Science ®Google Scholar
• DrakeCGAntonarakisESCurrent status of immunological approaches for the treatment of prostate cancerCurr Opin Urol201222319720222328018
   PubMed Web of Science ®Google Scholar
• SonpavdeGDi LorenzoGHiganoCSKantoffPWMadanRShoreNDThe role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literatureEur Urol201261463964722036643
   PubMed Web of Science ®Google Scholar
• FishmanMA changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancerExpert Opin Biol Ther20099121565157519916735
   PubMed Web of Science ®Google Scholar
• WardJEMcNeelDGGVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancerExpert Opin Biol Ther20077121893190218034654
   PubMed Web of Science ®Google Scholar
• IsaacsJTThe biology of hormone refractory prostate cancer. Why does it develop?Urol Clin North Am199926226327310361549
   PubMed Web of Science ®Google Scholar